Trial Search Results

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer

Stanford is currently not accepting patients for this trial.

Lead Sponsor:


Stanford Investigator(s):


  • Drug: olaparib
  • Drug: paclitaxel
  • Drug: carboplatin
  • Drug: paclitaxel
  • Drug: Drug: carboplatin


Phase 2


Inclusion Criteria:

   - Diagnosed with serous ovarian cancer

   - Patients who have received no more than 3 previous platinum containing treatments and
   were progression free for at least 6 months following the end of the last platinum

   - At least one lesion that is suitable for accurate repeated measurements

Exclusion Criteria:

   - Patients receiving any systemic anticancer chemotherapy, radiotherapy (except
   palliative) within two weeks from the last dose prior to study treatment

   - Hypersensitivity to pre medications required for treatment with paclitaxel/carboplatin

Ages Eligible for Study

18 Years - 125 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting